Tecentriq (Atezolizumab)

What is Tecentriq?

In 2016, the U.S. Food and Drug Administration (FDA) approved Tecentriq for urothelial carcinoma. It refers to cancers from the genitourinary tract up to the kidneys, including the bladder. Later that year, the FDA approved it as a second-line treatment for non-small cell lung cancer.

The FDA granted a priority review to Tecentriq in 2018 based on positive results from an ongoing clinical trial. If approved, Tecentriq could be added to the first-line chemotherapy regimen for advanced lung cancer.

Researchers presented the results of a trial at the 2021 American Society of Clinical Oncology Annual Meeting. They suggest similar benefits from Tecentriq when used to treat earlier-stage cancers.

Patients on Tecentriq after chemotherapy had a 21% reduction in the risk of disease recurrence or death. Progression-free survival was 42.3 months compared with 35.3 months in patients not treated with immunotherapy.

Tecentriq is available to pleural mesothelioma patients through clinical trials.

How Tecentriq Works

Tecentriq inhibits the same immune checkpoint as the immunotherapy drugs Keytruda (pembrolizumab) and Opdivo (nivolumab). Blocking the PD-L1 protein on cancer cells allows the body’s immune system to recognize and attack them.

The human body uses a type of white blood cell called T cells to defend itself from germs and cancer cells. T cells have a protein receptor on their surface called PD-1. When this protein interacts with another protein called PD-L1, it stops the T cell from attacking.

Healthy cells have PD-L1 on their surface so T cells know to leave them alone. But cancer cells can use PD-L1 to hide from the immune system by pretending to be healthy cells.

In many cases of pleural mesothelioma, the cancer cells express PD-L1. This is why doctors are testing checkpoint inhibitors such as Tecentriq for mesothelioma. Doctors usually combine this class of drugs with other treatments such as chemotherapy, surgery and radiation therapy.

Tecentriq Information
Name	Tecentriq
Alternate Names	Atezolizumab
Manufacturer	Genentech
Dosage	1200 mg every 3 weeks
Administration Route	IV
Active Ingredient	Atezolizumab
Drug Class	PD-L1 Inhibitor
Medical Code	50242-917-01, 50242-917-86
Related Drugs	Bavencio, Imfinzi
FDA Warning	Lung problems (pneumonitis), liver problems (hepatitis), intestinal problems (colitis), hormone gland problems, nervous system problems (neuropathy, meningitis, encephalitis), inflammation of eyes, severe infection, allergic reaction

Based on Your Reading:

Get a Mesothelioma Treatment Guide

Request Yours Today

Find a Top Mesothelioma Doctor

Find Your Doctor

Access Help Paying for Treatment

Get Help Now

Tecentriq in Mesothelioma Clinical Trials

A phase I trial of Tecentriq for advanced solid tumors began recruiting in 2015.

In 2017, another phase I trial began recruiting pleural mesothelioma patients eligible for surgery. This trial is testing whether Tecentriq is safe and effective in combination with multimodal therapy.

Patients may have the opportunity to join a clinical trial by going to a specialized cancer treatment center. Participation in clinical trials helps researchers develop and improve treatments. Some patients are able to access new therapies that help them live longer.

In 2018, early results from a phase III trial of Tecentriq for lung cancer showed promise. All patients in the trial received a standard chemotherapy regimen for metastatic non-small cell lung cancer. An experimental group of patients received Tecentriq in addition.

Of the patients who received Tecentriq, 37 percent went a full year without cancer progression, compared to 18 percent of patients in the control group.

Side Effects of Tecentriq

Checkpoint inhibitors such as Tecentriq usually cause milder side effects than chemotherapy drugs.

However, there is a risk of severe side effects if the immune system begins to accidently attack the body’s healthy cells. Patients with severe side effects must call their medical team immediately.

Balancing rest and activity may improve fatigue. Eating smaller meals helps with nausea and lack of appetite. Drink plenty of water and consume fiber to reduce constipation.

Patients experiencing side effects should contact their doctor for guidance. Quick treatment may prevent side effects from worsening.

Recommended Reading